ONCY ONCOLYTICS BIOTECH INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1129928 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-639.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets228.7%
Debt / equity—
Current ratio0.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-145.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY2023*2023-12-31 · CAD | FY2022*2022-12-31 · CAD | FY2021*2021-12-31 · CAD |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | 0 |
| R&D expense | $13.31M | $15.44M | 17.71M | 15.43M | 12.92M |
| SG&A expense | $15.41M | $10.10M | 16.08M | 11.49M | 13.31M |
| Operating income | -$28.73M | -$25.54M | -33.79M | -26.92M | -26.23M |
| Pretax income | -$28.68M | -$22.70M | -27.66M | -24.75M | -26.25M |
| Income tax | $79,000 | $95,000 | 97,000 | 84,000 | 49,000 |
| Net income | -$28.76M | -$22.79M | -27.75M | -24.84M | -26.30M |
| EBITDA | -$28.66M | -$25.45M | -33.71M | -26.83M | -26.11M |
| EPS (basic) | -0.30 | -0.30 | -0.41 | -0.43 | -0.49 |
| EPS (diluted) | -0.30 | -0.30 | -0.41 | -0.43 | -0.49 |
| Weighted avg. shares (diluted) | 95.86M | 76.48M | 67.62M | 58.03M | 53.51M |
| Banking | |||||
| Net interest income | — | -139,000CAD | -71,000 | 76,000 | -92,000 |
| Balance sheet | |||||
| Cash & equivalents | $5.20M | $11.08M | 34.91M | 11.67M | 41.26M |
| Current assets | $6.84M | $12.44M | 38.17M | 35.68M | 44.90M |
| PP&E, net | $228,000 | $286,000 | 282,000 | 356,000 | 392,000 |
| Total assets | $7.58M | $13.42M | 38.82M | 37.33M | 45.88M |
| Current liabilities | $6.10M | $4.88M | 4.24M | 3.94M | 2.69M |
| Total liabilities | $11.38M | $10.12M | 11.26M | 10.83M | 9.78M |
| Shareholders' equity | -$3.80M | $3.30M | $19.60MUSD | 26.50M | 36.10M |
| Shares outstanding | 108.02M | 80.02M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$20.11M | -$19.88M | — | — | — |
| Capital expenditure | $6,000 | $174,000 | 8,000 | 55,000 | 286,000 |
| Free cash flow | -$20.12M | -$20.06M | — | — | — |
| Investing cash flow | -$6,000 | -$174,000 | 20.22M | -20.40M | -286,000 |
| Financing cash flow | $14.12M | $5.03M | 31.99M | 12.21M | 33.02M |
| Depreciation & amortization | $70,000 | $87,000 | 81,000 | 93,000 | 130,000 |
| Stock-based compensation | $3.10M | $1.98M | 1.92M | 2.38M | 3.83M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.